Navigation Links
New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015

WASHINGTON, July 29, 2014 /PRNewswire-USNewswire/ -- New high priced hepatitis C drugs will increase federal spending in Medicare Part D by a projected $2.9 to $5.8 billion next year, according to a new report by the actuarial firm Milliman released today by the Pharmaceutical Care Management Association (PCMA). Milliman projects that average Part D premiums could increase by as much as 8.6 percent in 2015 as a result of high-priced hepatitis C drugs, including Sovaldi and Olysio.

The study finds that the majority of new Federal spending will come from increased federal reinsurance subsidies. Medicare payments for Part D catastrophic coverage have grown considerably faster than other components of Part D spending. According to the Medicare Payment Advisory Commission, between 2007 and 2012, payments have increased at an average annual rate of 14 percent while nearly doubling from $8 billion to $15.6 billion.

Milliman bases its cost projections on the assumption that 15 percent to 30 percent of the Medicare Part D population estimated to be infected with hepatitis C will receive an $84,000 course of treatment in 2015.

"While most payers cover about 75 percent of an enrollee's prescription drug costs, Medicare Part D covers 95 percent at high spending levels," said PCMA President and CEO Mark Merritt. "The study shows taxpayers will bear the lion's share of the increased drug costs for Medicare Part D beneficiaries taking hepatitis C drugs."

Click here to read the new report.

Major findings from the report include:

  • New hepatitis C drugs, including Sovaldi and Olysio, will increase 2015 federal spending on Medicare Part D by $2.9 to $5.8 billion for beneficiaries enrolled in Medicare Prescription Drug Plans (PDPs), an increase of $100 to $200 per beneficiary per year.
  • Average monthly premiums for Medicare PDPs are projected to increase 4.3 percent to 8.6 percent next year as a result of new hepatitis C drugs, an increase of $17 to $33 per beneficiary per year.

Milliman's analysis measured the impact of these new drugs on the Medicare Part D program; the study did not include the effect of the drug therapy on other medical costs.

PCMA represents the nation's pharmacy benefit managers (PBMs), which improve affordability and quality of care through the use of electronic prescribing (e-prescribing), generic alternatives, mail-service pharmacies, and other innovative tools for 216 million Americans.

Follow PCMA on Twitter

SOURCE Pharmaceutical Care Management Association
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Annual Healthcare Cost for a Typical American Family is $22,030 According to 2013 Milliman Medical Index
2. National Study: Teen "Heavy" Marijuana Use Up 80 Percent Since 2008, One in Ten Teens Reports Using Marijuana at Least 20 Times a Month
3. Inaugural Harris Poll Physician Pulse(SM) Study: Viagra® and Cialis® are Highest Ranked in Trust
4. Clinical Study: Dietary Supplement SagaPro Reduces Frequent Urination
5. WebMD Study: U.S. Doctors Deeply Divided on Many Matters of Ethical Ambiguity
6. Prostate Cancer Study: Most Patients Report Satisfaction After Robotic Surgery
7. Study: Surefire Medicals Technology Improves Delivery Of Embolics In Cancer Treatment
8. National Study: Teen Misuse and Abuse of Prescription Drugs Up 33 Percent Since 2008, Stimulants Contributing to Sustained Rx Epidemic[1]
9. NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied
10. New Study: Medicare Preferred Pharmacy Network Plans Offer Lower Average Premiums, Same Quality as Non-Preferred Network Plans
11. New Study: H.R. 4577 to Cost $21 Billion over 10 Years
Post Your Comments:
(Date:10/13/2015)... 2015  Nanomedical Diagnostics, a biotech company developing ... diagnostics, announces the completion of a Series A ... Ventures. --> ... monitoring and diagnostic platforms that empower individuals to ... will enable the company to commercially release AGILE ...
(Date:10/13/2015)... Oct. 9, 2015 Research and Markets ( ... "Kombucha Market by Types (Bacteria, Yeast, Mold, Others), Flavors ... Flowers, Others), & by Region - Forecasts to 2020" ... --> --> The global ... few years. In terms of value, the market is ...
(Date:10/13/2015)... Oct. 13, 2015   Micell Technologies , Inc. ... and II trials of its MiStent Sirolimus Eluting Absorbable ... ) were presented at the 27th Annual Transcatheter Cardiovascular ... San Francisco , October 11-15. TCT is the ... MiStent SES was designed to optimize vessel healing in ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... Boulder native and lifelong athlete, Mark ... power. Tested by Olympic and professional athletes, he developed the combined massage and ... in sporting equipment and high-tech sales led him to transition from Rally Software ...
(Date:10/13/2015)... FL (PRWEB) , ... October 13, 2015 , ... Vision ... Laser Vision of San Diego, California. With brands including The LASIK Vision Institute and ... procedures, making it the nationwide leader in laser vision correction. , Global Laser Vision ...
(Date:10/13/2015)... PITTSBURGH, PA (PRWEB) , ... October 13, 2015 , ... ... and digging his fists into his infected cheeks," said an inventor from Platteville, Colo. ... irritating their skin problems." , He developed the UNTOUCHABLE to prevent a child from ...
(Date:10/13/2015)... ... October 13, 2015 , ... HealthAware ... at HIMSS’s Patient Engagement Summit . HealthAware is a technology company focused ... programs and interventions via mobile devices that provide a framework for the development ...
(Date:10/13/2015)... ... 13, 2015 , ... Altec Products, Inc., the leader in ... Dynamics AXUG, GPUG and NAVUG Summits to take place the week of October ... user conferences designed and led by users to provide attendees with a unique ...
Breaking Medicine News(10 mins):